logo
Scientists create mind-bending material capable of sucking water out of thin air — here's how it could transform indoor air quality

Scientists create mind-bending material capable of sucking water out of thin air — here's how it could transform indoor air quality

Yahoo11-02-2025
A team of researchers has unlocked a potentially game-changing innovation that could revolutionize air quality in indoor spaces. The scientists created walls and ceilings that can basically suck water from the air and store moisture until the room can be properly ventilated later.
After the horrors of COVID-19, people became much more aware of indoor air quality. Sales of humidifiers and air purifiers skyrocketed. However, those devices can't stop a simple fact of science: When groups of people gather in tight spaces, the air will inevitably become thick with humidity.
Most office buildings and schools are equipped with mechanical ventilation. While these systems are effective, they can be extremely expensive and use a ton of energy.
The scientists from ETH Zurich sought to solve that problem by using the waste from marble quarrying as building materials. They then used metakaolin and an alkaline solution as a binder and built a wall and ceiling with a 3D printer.
For the experiment, the team simulated a reading room with 15 people at a public library in Portugal — and it was thrilled with the results.
"We were able to demonstrate with numerical simulations that the building components can significantly reduce humidity in heavily used indoor spaces," said building physicist Magda Posani, one of the leaders of the study.
This breakthrough is huge for potential construction going forward. The materials and 3D-printing method are more cost-effective than traditional components. They are also better for the environment. A switch to these types of materials over traditional mechanical ventilation and dehumidifier technology could significantly reduce pollution over time.
This is not the only technological advancement addressing the problem of indoor humidity. A company called Adept Materials recently developed a type of paint and primer that can also absorb moisture.
When we think about protecting the environment, many of us consider personal choices such as recycling or driving electric vehicles. While personal responsibility matters, buildings, retail stores, and office spaces are also important fronts in the battle to preserve our environment. That's why the researchers' innovation is so important.
Do you worry about the quality of the air inside your home?
Yes — often
Yes — but only sometimes
Only when it's bad outside
No — I never do
Click your choice to see results and speak your mind.
Future buildings are not the only ones tackling this problem. Corporations such as Kohl's have committed to using energy-efficient LED lighting in their stores and warehouses. Kohl's has even installed solar panels at some of its locations.
The scientists based out of Switzerland hope to build on this work and continue their research. The country set an ambitious goal to be net zero by 2050. In other words, it doesn't want to be releasing any gas pollution by then. To achieve this goal, it needs to construct extremely environmentally friendly buildings, and this research is an important step forward.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zespri Achieves a First for Fresh Produce with EU-Approved Health Claim for Green Kiwifruit
Zespri Achieves a First for Fresh Produce with EU-Approved Health Claim for Green Kiwifruit

Business Wire

time10 minutes ago

  • Business Wire

Zespri Achieves a First for Fresh Produce with EU-Approved Health Claim for Green Kiwifruit

ANTWERP, Belgium--(BUSINESS WIRE)--Green kiwifruit has become the first fresh fruit ever to receive an authorised health claim from the European Commission, marking a breakthrough for kiwifruit marketer Zespri and the wider fresh produce industry. Green kiwifruit is the first fresh fruit to achieve a health claim by the EU Commission, following more than 15 years of Zespri-led research Share The European Commission has officially approved the health claim that "consumption of green kiwifruit contributes to normal bowel function by increasing stool frequency" – based on a daily intake of two fresh green kiwifruit (Actinidia deliciosa var. Hayward) providing a minimum of 200g of flesh. This authorisation is among only three health claims approved by the European Commission in the last five years, following a rigorous evaluation process in which only less than 1 out of 8 claims submitted receive approval. Zespri CEO Jason Te Brake says, 'This milestone is not only a first for Zespri but for the entire fresh produce industry. The EU Commission's recognition of green kiwifruit's role in digestive health reflects one of the ways we are helping people thrive through the goodness of kiwifruit. The approval not only validates Zespri's health and innovation programme, it also delivers tangible value to the industry and reflects the hard work of our green growers to produce nutritious, great-tasting kiwifruit.' Zespri fully funded the application process and majority of the key research submitted in the scientific substantiation, committing over 15 years to documenting the benefits of green kiwifruit. The approval follows the submission of a comprehensive scientific dossier in 2018 which included 18 human intervention studies, six of which ultimately were considered as a strong basis for proving the effect of green kiwifruit on intestinal function. The European Food Safety Authority (EFSA) delivered a positive scientific opinion in 2021, which has now culminated in the Commission's formal authorisation. This landmark achievement demonstrates the critical value of investing in health and nutrition science -both to build trust in the fresh category and to unlock further growth and demand for green kiwifruit. In 2024/25, Zespri supplied a total of 220.9 million trays (Zespri TM Green, Zespri TM RubyRed TM and Zespri TM SunGold TM Kiwifruit) to more than 50 markets. Zespri Green kiwifruit is packed with essential nutrients including fiber, the beneficial effects on digestive health of which are well-documented in scientific research. The European Commission has now recognized the benefits of green kiwifruit for promoting good bowel habits, confirming the added value of this delicious fruit that many consumers already experience through daily consumption. As European consumers become increasingly proactive about their health and seek naturally nutritious foods with proven benefits, Zespri's leadership sets a blueprint for fresh produce that science-led innovation delivers real value for consumers and the industry. With this new authorisation, Zespri will begin integrating the health claim into its European communications, reaffirming its commitment to helping consumers make informed choices about their health. IMAGERY Imagery of Zespri Green Kiwifuit can be found in the following link LINKS Official Journal of the European Union: EFSA health claims page: ABOUT ZESPRI Zespri is 100 percent owned by current and former kiwifruit growers and has a global team of 900+ based in Mount Maunganui and throughout Asia, Europe and the Americas. Our purpose is to help people, communities and the environment thrive through the goodness of kiwifruit, and we work with 2,800 growers in New Zealand and 1,500 growers offshore to provide consumers with fresh, healthy and great-tasting Zespri Green, Zespri RubyRed and SunGold Kiwifruit. In 2024/25, we supplied 220.9 million trays (more than 795,000 tonnes) of kiwifruit to consumers in more than 50 markets, and recorded global operating revenue of NZ$5.14 billion. Zespri is committed to sustainability, with areas of improvement identified right through the supply chain including our pledge that by 2025 we will use 100 percent reusable, recyclable or compostable packaging, do more to help the environment, and work with our partners to be carbon positive by 2035.

UChicago Medicine hopes to expand its cancer care nationwide, announces first affiliation with Kansas hospital
UChicago Medicine hopes to expand its cancer care nationwide, announces first affiliation with Kansas hospital

Miami Herald

time3 hours ago

  • Miami Herald

UChicago Medicine hopes to expand its cancer care nationwide, announces first affiliation with Kansas hospital

UChicago Medicine hopes to expand its cancer care across the country - becoming the latest hospital system to try to grow by working with health systems outside its home turf. UChicago Medicine announced its first affiliation Tuesday with AdventHealth Cancer Institute Shawnee Mission in the Kansas City area. As part of the affiliation, patients at the Kansas cancer institute will have access to UChicago Medicine treatments, clinical trials and second opinions from UChicago Medicine doctors. The Kansas cancer institute will remain an independent entity but align with UChicago Medicine when it comes to standards in clinical care, medical education and research. A UChicago Medicine spokesperson did not answer questions about the financial details of the arrangement. The UChicago Medicine Cancer Network is "uniquely positioned to provide expertise nationwide," said Dr. Kunle Odunsi, director of the UChicago Medicine Comprehensive Cancer Center. U.S. News & World Report ranks University of Chicago Medical Center as the 12th best hospital for cancer in the country and the best hospital for cancer in the Chicago area. "The goal is to take these types of opportunities to communities where patients live so that a patient in Kansas does not have to travel to Chicago to receive UChicago Cancer Center type of care," Odunsi said. "They can remain in their local area and have incredible access just like anyone who lives in our region." Dr. Brenda Shoup, medical director of AdventHealth Cancer Institute, said in a news release, "We're bringing nationally recognized expertise and innovation to our community - ensuring our patients have access to the latest treatments and research without having to travel far." It could be the first of a number of affiliations for the UChicago Medicine Cancer Network. UChicago Medicine is beginning discussions with other health systems about additional affiliations, Odunsi said. "We continue to invest (locally) but we believe that we have a lot to offer beyond our local region, a lot to offer across the country, so there is no specific number right now (of possible affiliations) but where the opportunities arise we will take advantage of those opportunities," Odunsi said. UChicago Medicine joins a growing trend, as it works to collaborate with health systems across the country for cancer care. Rush University System for Health partnered with University of Texas MD Anderson Cancer Center last year. U.S. News & World Report ranks MD Anderson Cancer Center as the No. 1 cancer hospital in the country. Related Articles • Mokena fundraiser offers connections for people with neuromuscular disease • Walmart recalls frozen shrimp over potential radioactive contamination • US pediatricians' new COVID-19 shot recommendations differ from CDC advice • Abbott Laboratories scores a win in federal court, as it faces hundreds of suits over formula for preterm babies • ICE spared him from deportation to Venezuela. He donated a kidney to save his ailing brother in the Chicago area. Under that partnership, the Rush Cancer Center was renamed as the Rush MD Anderson Cancer Center. Rush said, when the partnership was announced, it would allow protocols and cancer treatment plans at Rush to mirror those available at MD Anderson, give patients access to more clinical trials, and allow Rush doctors to consult with MD Anderson doctors on treatment decisions. Rush is one of seven health systems across the country that have partnered with the MD Anderson Cancer Network. Northwestern Medicine also, in the past year, announced collaborations with multiple Florida health systems. In June, Northwestern announced a collaboration with Florida's BayCare that would give BayCare access to more medical treatments, clinical research and training opportunities for current and future physicians in west central Florida. Last fall, Northwestern said it would collaborate with Florida's Naples Comprehensive Health, allowing Naples' to take advantage of Northwestern's clinical trials, oncology experts and offer its patients second opinions from Northwestern doctors. Health systems are increasingly focusing on cancer care, with demand climbing as baby boomers age. The Centers for Disease Control & Prevention has projected a 49% increase in annual cancer cases between 2015 and 2050. Chicago-area hospitals have been working to expand and improve their cancer offerings locally as well. UChicago Medicine is building a 575,000-square-foot freestanding cancer hospital on Chicago's South Side. Scheduled to open in 2027, that cancer center is intended to give South Side residents greater access to cancer care while attracting patients from across the region. Northwestern is also hoping to build a new tower on its Streeterville campus with more than 200 beds that would also consolidate oncology services now spread across five buildings on the hospital campus. Endeavor Health is adding a two-story addition to its Knowles Cancer Center at Endeavor Health Elmhurst Hospital, and converting a floor of the Galter Medical Pavillion at Endeavor Health Swedish Hospital into a cancer space with additional rooms. UChicago Medicine previously acquired a controlling interest in four AdventHealth hospitals in west suburban Bolingbrook, Glendale Heights, Hinsdale and La Grange. That deal, however, involved only AdventHealth's Great Lakes Region. AdventHealth has hospitals and care sites across nine states. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Indianapolis Star

time5 hours ago

  • Indianapolis Star

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store